Matthew Johnson, MD
Ophthalmology · Sycamore, ILNPI 1912133638
Payments from drug & device makers
What this record shows
15 manufacturers reported payments, led by Omeros Corporation at 47.8% of the total. Reporting peaked in 2021 at $1,134 and has fallen 87.4% since, to $143 in 2025.
Across 37 payments — averaging $58.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Omeros Corporation$1K
- Biotissue Holdings Inc.$276
- Alcon$232
- Harrow Eye, LLC$163
- Carl Zeiss Meditec USA, Inc.$120
- Novartis$78
- plus $261 from 9 others
What the payments were for
- Consulting fees$89541%
- Food & beverage$1,27359%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Omeros Corporation | 4 | $1,037 |
| Biotissue Holdings Inc. | 3 | $276 |
| Alcon | 12 | $232 |
| Harrow Eye, LLC | 1 | $163 |
| Carl Zeiss Meditec USA, Inc. | 1 | $120 |
| Novartis | 4 | $78 |
| Sight Sciences, Inc. | 2 | $49 |
| Sun Pharmaceutical Industries Inc. | 3 | $48 |
| Merz North America, Inc. | 1 | $31 |
| Apellis Pharmaceuticals, Inc. | 1 | $31 |
| Thea Pharma Inc. | 1 | $24 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMIDRIA$999
- Prokera$171
- AmnioGraft$171
- IHEEZO$163
- CLARUS 500$120
How this compares
$2,168 in reported general payments places this provider in the 60th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 295 | $102,251 |
| LumiganBimatoprost | 92 | $40,141 |
| Bromfenac Sodium | 159 | $35,417 |
| RestasisCyclosporine | 29 | $22,828 |
| MoxifloxacinMoxifloxacin Hcl | 1,016 | $18,312 |
| Prednisolone Acetate | 599 | $15,419 |
| RhopressaNetarsudil Mesylate | 43 | $14,808 |
| VyzultaLatanoprostene Bunod | 21 | $10,559 |
| Brimonidine Tartrate | 259 | $10,164 |
| RocklatanNetarsudil Mesylat/Latanoprost | 29 | $9,901 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $8,426 |
| Cyclosporine | 22 | $6,947 |
| Latanoprost | 769 | $6,774 |
| Ketorolac Tromethamine | 504 | $5,923 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 35 | $5,656 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $22 | $24,71072 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $24 | $10,55921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Sycamore
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
- Yannek LeidermanChicago$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.